Utilization Rates of Contraceptive Methods in Patients with Rheumatic Disorders: A Descriptive Analysis - Takeaways - MDSpire

Utilization Rates of Contraceptive Methods in Patients with Rheumatic Disorders: A Descriptive Analysis

  • By

  • Mayalen Uthurriague

  • Charlotte Delattre

  • Thomas Barnetche

  • Estibaliz Lazaro

  • Marie-Elise Truchetet

  • Claude Hocke

  • Nadia Mehsen-Cetre

  • Valérie Bernard

  • Christophe Richez

  • February 12, 2026

  • 0 min

Share

  • 1

    Women with rheumatic diseases face higher risks during pregnancy, including adverse outcomes like fetal loss and preeclampsia.

  • 2

    Effective contraception is crucial for women with systemic autoimmune diseases to prevent unplanned pregnancies that pose significant risks.

  • 3

    The study evaluated contraceptive use among women with various rheumatic disorders, including lupus and rheumatoid arthritis.

  • 4

    Data were collected through a standardized questionnaire assessing reproductive health and contraceptive practices from July 2023 to July 2024.

  • 5

    The MARIGYN project was approved by the French Ethics Committee and aims to improve understanding of contraception in patients with rheumatic diseases.

Original Source(s)

Utilization Rates of Contraceptive Methods in Patients with Rheumatic Disorders: A Descriptive Analysis

  • by Mayalen Uthurriague, Charlotte Delattre, Thomas Barnetche, Estibaliz Lazaro, Marie-Elise Truchetet, Claude Hocke, Nadia Mehsen-Cetre, Valérie Bernard, Christophe Richez

  • February 12, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.